eMedevents
  • 154,522+ Medical Conferences
  • 285 Specialties
  • 11,293 Organizers
  • 156,433 Speakers
  • 159 Countries
  • 4,785 Cities
51,507+
CME Conference Registrations Sold

SEARCH NEWS
Or

Daily BCX7353 Cuts Rate of Hereditary Angioedema Attacks

Daily BCX7353 Cuts Rate of Hereditary Angioedema Attacks

Thu, Jul 26, 2018

THURSDAY, July 26, 2018 (HealthDay News) -- A small-molecule inhibitor of plasma kallikrein, BCX7353, results in a significantly lower rate of hereditary angioedema attacks compared with placebo, according to a study published in the July 26 issue of the New England Journal of Medicine.

Emel Aygören-Pürsün, M.D., from University Hospital Frankfurt in Germany, and colleagues randomized 77 patients with type I or II hereditary angioedema with a history of at least two angioedema attacks per month to BCX7353 (at four doses: 62.5, 125, 250, and 350 mg) or placebo. Seventy-two of the patients completed the trial.

The researchers found that patients who received BCX7353 at daily doses of 125 mg or more had a significantly lower rate of confirmed angioedema attacks compared with those who received placebo, with a 73.8 percent difference at 125 mg. The 125- and 250-mg groups had significant benefits with respect to quality-of-life scores. The most commonly reported adverse events were gastrointestinal adverse events, mainly grade 1, especially in the two highest BCX7353-dose groups.

"Once-daily oral administration of BCX7353 at a dose of 125 mg or more resulted in a significantly lower rate of attacks of hereditary angioedema than placebo," the authors write. "Longer studies will need to be performed to assess the safety profile of long-term dosing."

The study was funded by BioCryst Pharmaceuticals, the manufacturer of BCX7353.

Abstract/Full Text (subscription or payment may be required)